← Back
Data updated: Mar 10, 2026
YICHANG HUMANWELL
CardiovascularInfectious DiseaseNeurology
YICHANG HUMANWELL is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology.
2018
Since
19
Drugs
-
Trials
343
Approved (2yr)
Recent Activity
BUPROPION HYDROCHLORIDE 2026-02-25
Labeling
MICAFUNGIN SODIUM 2026-02-24
VENLAFAXINE HYDROCHLORIDE 2026-01-30
Labeling
DIVALPROEX SODIUM 2026-01-29
Labeling
DIVALPROEX SODIUM 2026-01-29
Labeling
DIVALPROEX SODIUM 2026-01-28
Labeling
DIVALPROEX SODIUM 2026-01-28
Labeling
DIVALPROEX SODIUM 2026-01-24
Labeling
DIVALPROEX SODIUM 2026-01-24
Labeling
DIVALPROEX SODIUM 2026-01-24
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 40%
2 drugs
Infectious Disease 20%
1 drugs
Neurology 20%
1 drugs
Immunology 20%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Merck big-pharma
Infectious Disease, Cardiovascular, Immunology
AbbVie big-pharma
Immunology, Neurology, Infectious Disease
PAI HOLDINGS PHARM big-pharma
Infectious Disease, Neurology, Cardiovascular, Immunology
Johnson & Johnson big-pharma
Immunology, Infectious Disease, Cardiovascular
GSK big-pharma
Infectious Disease, Immunology, Neurology
Active (11)
Discontinued (8)
Company Info
- First Approval
- 2018-06-14
- Latest
- 2026-02-24
- Applications
- 23